Reinforcement, dopamine and rodent models in drug development for ADHD.
Attention deficit hyperactivity disorder (ADHD) presents special challenges for drug development. Current treatment with psychostimulants and nonstimulants is effective, but their mechanism of action beyond the cellular level is incompletely understood. We review evidence suggesting that altered reinforcement mechanisms are a fundamental characteristic of ADHD. We show that a deficit in the transfer of dopamine signals from established positive reinforcers to cues that predict such reinforcers may underlie these altered reinforcement mechanisms, and in turn explain key symptoms of ADHD. We argue that the neural substrates controlling the excitation and inhibition of dopamine neurons during the transfer process are a promising target for future drug development. There is a need to develop animal models and behavioral paradigms that can be used to experimentally investigate these mechanisms and their effects on sensitivity to reinforcement. More specific and selective targeting of drug development may be possible through this approach.
Human Developmental Neurobiology Unit, Okinawa Institute of Science and Technology Graduate University, Kunigami, Okinawa 904-0412, Japan. tripp@oist.jp
Gail
G
Tripp
Jeff
J
Wickens
D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D012054:Reinforcement, Psychology; D012377:Rodentia
D015259:Dopamine Agents; D004298:Dopamine